Conclusion. Ceftobiprole is a novel, broad-spectrum, parenteral cephalosporin undergoing Phase III clinical trials. Its broad spectrum of activity makes it a candidate for monotherapy of cSSSIs ...

coli is resistant to third-generation cephalosporin — a commonly prescribed ... which is also drug-resistant. Pseudomonas aeruginosa leads to infections in the blood, lungs, urinary tract ...

Ceftobiprole is a fifth-generation cephalosporin antibiotic that has ... had limited activity against certain strains of Pseudomonas aeruginosa, emphasizing the need for susceptibility testing ...